Samsung Biologics readies mRNA vaccine drug substance production

By The Science Advisory Board staff writers

June 1, 2021 -- Samsung Biologics said that it plans to add messenger RNA (mRNA) vaccine drug substance production to its suite of manufacturing capabilities.

The company's current facility in Songdo, South Korea, is expected to be capable of current good manufacturing practice (cGMP) operations for mRNA vaccine drug substance production by the first half of 2022. As a result, Samsung Biologics will be able to provide end-to-end mRNA vaccine manufacturing services, ranging from bulk substances to aseptic fill/finish including labeling and packaging, as well as cold chain storage, according to the vendor.

Moderna inks South Korean mRNA vaccine collaborations
Moderna has inked two memoranda of understanding agreements with South Korea for messenger RNA (mRNA) vaccine research and manufacturing in that country.
Samsung Biologics breaks ground on 'super plant'
Samsung Biologics broke ground on the construction of its biopharma manufacturing facility Plant 4 in Incheon, South Korea during a virtual ceremony.
Lilly partners with Samsung Biologics to manufacture COVID-19 antibodies
Eli Lilly and Samsung Biologics have signed a long-term partnership for manufacturing of Lilly's COVID-19 antibody therapies.
Samsung Biologics partners on antibody development, manufacturing
Samsung Biologics has announced that its contract development and manufacturing organization services have been selected by two companies for their antibody...
Samsung Biologics, BioEleven partner on cancer immunotherapy
Samsung Biologics has entered into a strategic partnership with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter